Kwan Gene, Isakson Susan R, Beede Jennifer, Clopton Paul, Maisel Alan S, Fitzgerald Robert L
Division of Cardiology, Department of Medicine, Veterans Affairs Healthcare System San Diego and University of California, San Diego, California 92161, USA.
J Am Coll Cardiol. 2007 Mar 20;49(11):1186-92. doi: 10.1016/j.jacc.2006.11.031. Epub 2007 Mar 6.
The purpose of this study was to characterize the diagnostic and prognostic utility of short-term dynamic changes in natriuretic peptides in patients presenting with chest pain.
Although single levels of natriuretic peptides in patients admitted for acute coronary syndromes (ACS) have important prognostic value, it is unclear whether serial sampling of natriuretic peptides might have both diagnostic and prognostic value in the setting of chest pain.
We followed 276 patients for 90 days who presented to the emergency department with chest pain. We sampled brain natriuretic peptide (BNP) and amino-terminal (NT)-proBNP up to 5 times within 24 h of presentation and again at discharge. Follow-up data was collected at 30 and 90 days after admission. Adverse events included emergency department visits for chest pain, cardiac readmission, and death. We assessed the prognostic and diagnostic value of baseline natriuretic peptide measurements with receiver-operating characteristic analyses.
Natriuretic peptides were diagnostic for congestive heart failure (CHF) and new-onset CHF but less so for ACS. The prognostic utility of serial sampling was evaluated through testing the statistical contribution of each future time point (as well as variability over time) over and above the baseline values in logistic regression models.
Baseline elevated BNP and NT-proBNP concentrations were predictive of adverse events at 30 and 90 days. Serial sampling did not improve the prognostic value of BNP or NT-proBNP.
本研究旨在描述胸痛患者利钠肽短期动态变化的诊断和预后效用。
尽管急性冠状动脉综合征(ACS)患者的单次利钠肽水平具有重要的预后价值,但尚不清楚在胸痛情况下连续采样利钠肽是否具有诊断和预后价值。
我们对276例因胸痛就诊于急诊科的患者进行了90天的随访。在就诊后24小时内对脑利钠肽(BNP)和氨基末端(NT)-proBNP进行了多达5次采样,并在出院时再次采样。在入院后30天和90天收集随访数据。不良事件包括因胸痛到急诊科就诊、再次入院和死亡。我们通过受试者操作特征分析评估了基线利钠肽测量的预后和诊断价值。
利钠肽对充血性心力衰竭(CHF)和新发CHF具有诊断价值,但对ACS的诊断价值较小。通过在逻辑回归模型中测试每个未来时间点(以及随时间的变异性)相对于基线值的统计贡献,评估了连续采样的预后效用。
基线BNP和NT-proBNP浓度升高可预测30天和90天的不良事件。连续采样并未提高BNP或NT-proBNP的预后价值。